Ozempic Personality: Are These Behavioural Changes Really Linked to the Drug?
As medications used to treat type 2 diabetes and obesity have become increasingly popular, one expression has attracted growing attention on social media: “Ozempic personality.” The term refers to emotional or behavioural changes that some people say they have experienced while taking these medications, including reduced motivation, less interest in certain activities, anxiety or a more depressed mood.
But does this widely discussed expression describe a scientifically established side effect? Current evidence does not establish that semaglutide, the active ingredient in Ozempic, directly causes a change in personality. Researchers are nevertheless continuing to investigate how these medications may affect the brain, emotions and behaviour.
What does “Ozempic personality” actually mean?
The term is not a recognised medical diagnosis. Instead, it encompasses a variety of personal experiences that can be difficult to compare. Some people describe losing interest in food, while others report changes in their mood, motivation or enjoyment of everyday activities.
These experiences should not automatically be attributed to the medication. Significant weight loss, changes in eating habits, persistent fatigue and personal difficulties can also influence behaviour and emotional well-being.
It is therefore important to distinguish individual accounts from side effects established through rigorous clinical research.
How do these medications affect the brain?
Ozempic contains semaglutide, a medication that mimics the action of GLP-1, a hormone involved in regulating blood sugar and appetite. It helps improve glucose control and influences the mechanisms responsible for hunger and satiety.
However, the brain systems involved in eating also interact with those responsible for motivation, learning and reward-seeking behaviour. Researchers are therefore investigating whether GLP-1 medications may influence certain behaviours beyond their effects on appetite.
This does not mean that semaglutide necessarily changes a person’s personality. The precise mechanisms behind any potential emotional or behavioural effects remain an area of investigation.
What does the scientific evidence show?
Clinical trial data have not established a consistent increase in psychiatric problems among people taking semaglutide. An analysis of several clinical trials involving people with overweight or obesity found no significant increase in depressive symptoms or suicidal thoughts and behaviours compared with placebo.
In January 2026, the US Food and Drug Administration (FDA) also announced that it was requesting the removal of warnings about suicidal thoughts and behaviours from the prescribing information of certain GLP-1 medications, including Wegovy and other affected treatments. The decision followed a comprehensive review that found no increased risk associated with these medications.
These findings are reassuring, but they do not mean that no individual can experience psychological difficulties while receiving treatment. Rather, they indicate that a general causal relationship between these medications and a systematic deterioration in mental health has not been established.
Why do some people report feeling different?
Several explanations are possible, although none independently confirms the existence of an “Ozempic personality”.
Weight loss can change how people perceive their bodies, interact socially and understand themselves. Changes in appetite and eating habits may also reshape daily routines, particularly for people who previously associated food with comfort or social occasions.
In addition, treatment-related symptoms such as nausea, digestive problems and fatigue may temporarily affect well-being. Emotional difficulties can also arise from factors unrelated to the medication, including stress, previous psychological problems or major life changes.
Finally, accounts shared on social media cannot establish how frequently these experiences occur or what causes them. Controlled studies remain essential for distinguishing coincidence from a genuine pharmacological effect.
What changes should patients monitor during treatment?
Persistent mood changes, unusual anxiety, a substantial loss of interest in everyday activities or an ongoing decline in motivation deserve attention, regardless of their cause.
People who notice such changes should discuss them with their healthcare provider, explaining when they began, how severe they are and whether they have become more pronounced over time. A healthcare professional can investigate possible causes, assess the situation and determine whether treatment adjustments are appropriate.
Patients should not stop taking their medication or change the prescribed dose without medical advice. Anyone experiencing suicidal thoughts or an acute psychological crisis should seek urgent medical assistance.
An open question for future research
“Ozempic personality” remains a popular expression rather than a formally defined medical side effect. Current evidence does not demonstrate that semaglutide routinely causes personality changes, but it also cannot rule out every possible individual reaction.
Further research is needed to clarify how these medications may affect emotions, motivation and behaviour, particularly among people with a history of mental health conditions.
For now, the most sensible approach is to avoid premature conclusions, distinguish personal accounts from scientific evidence and report any unusual changes that occur during treatment to a healthcare professional.
